Loading stock data…
BNTX
$86.20-0.29 (-0.34%)
Market OpenUpdated 1:31 PM EDT
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioNTech SE in the Healthcare sector is trading at $86.20. Wall Street consensus targets $122.99 (19 analysts), implying a +42.7% move over the next 12 months. The stock is currently near its 52-week low of $79.52, remaining 13.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +42.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $118.10M↓ | $907.40M↓ | $1.52B↑ | $260.80M↑ | $182.80M |
| Gross Profit | $46.70M↓ | $574.10M↓ | $1.37B↑ | $184.40M↑ | $99.00M |
| Operating Income | -$671.20M↓ | -$280.50M↓ | $653.90M↑ | -$478.50M↑ | -$561.50M |
| Net Income | -$531.90M↓ | -$305.00M↓ | -$28.70M↑ | -$386.60M↑ | -$415.80M |
Peer Comparison
JNJUNHPFE
Fundamentals
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.70%
Volume
Today's trading volume
529,763
Recent News
BioNTech (BNTX) and Bristol Myers Share New Results From ROSETTA Lung-02 Study
BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential. BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Company announced on May 30 interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig plus chemotherapy in patients with previously untreated advanced […]
Assessing BioNTech (BNTX) Valuation After Recent Share Price Weakness And Conflicting Growth Signals
BioNTech (BNTX) is back in focus after recent trading left the stock at a last close of US$88.08, with investors weighing its cancer and infectious disease pipeline against current revenue and earnings trends. See our latest analysis for BioNTech. That weaker 1 month share price return of 6.42% and year to date share price decline of 8.9%, alongside a 1 year total shareholder return fall of 19.2%, suggests recent momentum has cooled after a modest 90 day rebound. If BioNTech's recent pullback...
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index increasing 0.6% and
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European equities traded in the US as American depositary receipts started the trading week lower la
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
European equities traded in the US as American depositary receipts were rising late Friday morning,